Recombinant Proteins Market Outlook:
Recombinant Proteins Market size was over USD 3.01 billion in 2025 and is poised to exceed USD 7.26 billion by 2035, witnessing over 9.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of recombinant proteins is estimated at USD 3.26 billion.
The market growth is mainly owing to the increasing demand for biopharmaceuticals, advancements in biotechnology, and rising prevalence of chronic diseases across the globe. Moreover, diabetes, which is a chronic disease, is one of the most prevalent diseases across the globe. Diabetes damages many organs in the body, including the eyes, nerves, brain, kidneys, heart, and blood vessels. Rise in adults with chronic disease and diabetes is expected to increase the demand for recombinant proteins during the forecast period. For instance, in the year 2021 it was noted that more than 530 million adults have diabetes, which is expected to rise to about 640 million by the year 2030. Hence, this is also expected to be a major factor to add to the growth of the global market.
In addition to this, biopharmaceuticals represent one of the fastest-growing sectors within the pharmaceutical industry, with a projected global revenue size of nearly USD 520 billion by the year 2024. Recombinant proteins are a critical component of many biopharmaceuticals, making up approximately 60% of all approved biologic drugs. Recombinant proteins are proteins that are produced using recombinant DNA technology, also known as genetic engineering. This technology involves the insertion of a gene encoding a specific protein into a host organism, such as bacteria, yeast, or mammalian cells, which then produces the protein of interest. Recombinant proteins are used in a wide range of applications, including biopharmaceuticals, research and development, diagnostics, and industrial processes.
